🚨Our NEW paper out from POP-RT trial Vedang Murthy in IJROBP - The Red Journal !!!🤩

Elective pelvic #radiotherapy in HR-VHR #prostatecancer ⬆️ ⬆️BFFS, DFS, MFS

Does toxicity REALLY increase⁉️
Short: NO
Long: ~10% higher gr2 late urinary (p=NS)
1/

doi.org/10.1016/j.ijro…

Meet our Co-ambassador for Cyprus-Greece
Konstantina Stylianou, DAOM, RN
Head of Integrative Medicine Department
German Oncology Center Limassol, Cyprus
Co-Chair of Communications committee
#Integrativeoncology #oncology #integrativemedicine #wellness #Cyprus #Greece

Long term results Oligopelvis study European Urology
Congrats Supiot Stéphane
GETUG
🔆Median FU = 6.1 yr
🔆N=67
🔆Rates of grade 2+ toxicities among patients without progression at 5 yr was 4% for GU toxicities, and 4% for GI, respectively.

sciencedirect.com/science/articl…

For all who are interested in the multidisciplinary treatment of oropharyngeal carcinoma, I recommend the today's Deutsche Gesellschaft für Radioonkologie e.V. webinar (please note that talks are in German):
shorturl.at/lqtT4

The zoom-webinar starts at 5pm CET (no registration necessary)

#radonc #MedTwitter

Live demo of the INCISIVE platform showing over 30 #AI services that can detect, classify and prioritise images to streamline #cancer services INCISIVE project

1/ For #KidneyCancerAwareness month The Lancet Oncology has a 50-day full link to TROG Cancer Research FASTRACK II! authors.elsevier.com/a/1ifvZ5EIIgPd…. Thank you Cancer Australia, ANZUP, Varian. A new #radiotherapy standard of care option for inoperable primary #kidneycancer #radonc

Remember to vote! Your voice matters for the future of our discipline#ESTROElections

Quality of life in #BladderCancer : a comparative study on cystectomy vs bladder preservation. Vedang Murthy Tata Memorial Hospital joins Phillip Koo, MD Banner Health to discuss his study and the implications on UroToday. > bit.ly/3M40xPv ASTRO

94.1% efficacy at 5 years exceeded our wildest expectations.

#GU24 we saw IMPROVEMENT in:

🔥PFS (HR 0.56, 95%CI 0.40-0.76, p=0.0005)
🔥PCSS (HR 0.48, 95%CI 0.27-0.83, p=0.009)
🔥🔥OS (HR 0.61, 95%CI 0.44-0.85, p=0.0039) !!!!!

More pts received IMRT in 80 Gy arm…

🔥🔥check out the Best of Journals sessions, available now!! #GU24
Don't miss the Renal Cell Cancer session
Great job by all Constantinos Zamboglou Nazli Dizman Dr. Thomas Ng Dr. Adam Calaway 👏
ASCO

Thanks and congratulations to December's BJUI #ReviewersOfTheMonth James Blackmur Enrico Checcucci Ettore Di Trapani Luke Harper 👨🏼‍⚕️ & Constantinos Zamboglou

You can read more here: bjui-journals.onlinelibrary.wiley.com/doi/full/10.11…

Daniel Pennington, MD, PhD NRG Oncology Paul Nguyen Alejandro (Ale) Berlin You are correct - MRI based at present is only level 1 supported data to allow use in gu10. Simon Spohn Constantinos Zamboglou have a large/great body of work on trade off of psma sensitivity w larger sib volume and impact on dose selection of boost now being vetted in ongoing P3 trial.

#prostatecancer #radonc
60y, PSMA-PET staged, Post RARP and PLND:
EPE+, apical margin +ve, GG2
1/14 nodes +ve at CI.
PSA <0.01, continent.
pT3aN0M1a

Piet Ost Paul Sargos Derya Tilki, MD Alan Dal Pra, MD Amar Kishan Constantinos Zamboglou Advanced Prostate Cancer Consensus Conference Chris Parker Thomas Zilli Supiot Stéphane

The essence of data sharing. Gianna Tsakou comments that “no matter what are the challenges, the benefits of data sharing offers new possibilities and opportunities to improve care…” INCISIVE project TRANSiTION ShereenNabhaniGebara German Oncology Center Constantinos Zamboglou Lithin Zacharias

I am hopeful that the 2024 guideline panel will be more thoughtful about the evidence, embrace the data from these 3 prospective studies, and appreciate that it’s okay we were all misled for decades about the perceived superiority of surgery for early-stage NSCLC. National Comprehensive Cancer Network (NCCN) Journal of the @NCCN